The TNF inhibitors etanercept and adalimumab are thought to be equally effective in juvenile idiopathic arthritis (JIA). Nonetheless, a Dutch study shows that prescription patterns differ and offers insights into the factors influencing the choice of agent. During the study period, 193 eligible patients with JIA initiated treatment with etanercept and 21 were started on adalimumab. Focus groups suggested that the physician's greater experience of etanercept and the pain of adalimumab injections were key reasons for this disparity, whereas the presence of uveitis led to a preference for adalimumab.